Crohn's disease trials in United Kingdom

In United Kingdom 38 Also abroad 422

38 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Bristol, Cambridge, Doncaster, Exeter, Huddersfield, London, Oxford, Southampton, West Midlands
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 3Taking people
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Where
London, Prescot
Age
18 years and over
People
1,380 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00
Phase 3Taking people
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Where
Birmingham, London, Sheffield
Age
2 years to 17 years
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07298421 · EU 2025-523318-96-00
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Glasgow, London, Manchester, Oxford, Sheffield
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Sheffield, Stoke-on-Trent
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
No phaseTaking people
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
Where
Harrow
Age
18 years and over
People
220
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT07242248
No phaseTaking people
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
Where
Bury, Cambridge, Cottingham, Dudley, Llandough, London, Oxford, Southampton, Winchester
Age
18 years and over
People
378 worldwide
Run by
Alimentiv Inc.
See details and how to joinNCT07363044
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Greater London, Iselworth, London, Norwich, Wolverhampton
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Birmingham, Bury, Cardiff, Dundee, Dundonald, Exeter, Glasgow, London, Newcastle upon Tyne, Oxford
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Belfast, Cambridge, London
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Bury, Cambridge, Dagenham, London
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 2Taking people
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
Where
London
Age
18 years and over
People
320 worldwide
Run by
Agomab Spain S.L.U.
See details and how to joinNCT07683325
No phaseTaking people
Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study
Where
Coventry, Harrow, London, Newcastle upon Tyne, Oxford
Age
18 years and over
People
100
Run by
University Hospitals Coventry and Warwickshire NHS Trust
See details and how to joinNCT06579443
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Bristol, Bury, Llanrhystud, London, Newcastle upon Tyne, Stockport
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Cambridge, Cottingham, London, Norwich, Rochdale
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Birmingham, London, Sheffield
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
London, Oxford, Sheffield
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Bristol, Cardiff, Coventry, Edinburgh, Glasgow, London, Newcastle upon Tyne, Oxford, Wolverhampton
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
No phaseTaking people
Fibrosis Associated Protein Inhibitor (FAPI) Radiotracer-based Imaging to Identify Fibrotic Intestinal Crohn's Disease
Where
Edinburgh
Age
18 years to 90 years
People
30
Run by
University of Edinburgh
See details and how to joinNCT07152431
Phase 2Taking people
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
Where
Oxford
Age
18 years to 75 years
People
20
Run by
Takeda
See details and how to joinNCT07403968
No phaseTaking people
PIBD-SETQuality: the Inception Cohort and Safety Registry
Where
London
Age
0 years to 19 years
People
1,500 worldwide
Run by
Erasmus Medical Center
See details and how to joinNCT03571373
No phaseTaking people
NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
Where
Nottingham
Age
16 years and over
People
240
Run by
University of Nottingham
See details and how to joinNCT06956703